AI Visibility Tools for Life Sciences
Confidential. We work within quiet periods and blackout schedules.
Direct Answer
AI visibility in life sciences differs from other categories in three specific ways. First, the output has to be reviewable: medical, legal and regulatory teams need the AI-generated claim, its date and engine, and how it diverges from approved prescribing information — not a visibility percentage. Second, remediation is constrained by the disclosure calendar, including quiet periods, blackout windows, readouts and PDUFA dates. Third, the risk is claim-level accuracy — safety profiles drawn from class-level data, mechanisms of action that contradict the label, statements misattributed to your investigators — rather than share of voice. Generic AI visibility trackers collect data competently in any vertical; what they do not publish is a workflow built around review, approval and disclosure constraints.
Why generic AI visibility tools miss regulated industries
Let us be precise about the claim being made here, because it would be easy to overstate it. The trackers are not bad at their job. They query the same engines whether the brand is a running shoe or an oncology asset, and the measurement does not get less accurate because your category is regulated. On the data-collection side they do work we do not attempt — see the full capability comparison for the rows where they win outright.
What is true, and verifiable from their own pages, is who they built for:
- Profound — Solutions are organised under "For Teams" as AEO Teams, Content Teams and PR & Brand Teams. Enterprise adds SSO/SAML and SOC 2 compliance.
- Peec.ai — Headline reads "AI search analytics for marketing teams", with visibility, position and sentiment as the metrics.
- Otterly.ai — Plans are described for solo marketers, SMEs, agencies and global brands, tiered by search prompts and engines tracked.
None of the three publishes a life sciences or regulated-industry offering. That is a statement about positioning, not about capability, and it is the whole of our claim — we are not going to invent compliance failures they have never been accused of. The practical consequence is narrow but real: a product organised around marketing teams produces marketing-shaped output, and a regulated programme needs a different shape.
What a regulated programme actually requires
These five requirements are what separate a life sciences AI visibility programme from a brand-monitoring one. Judge any vendor, us included, against them.
1. Output an MLR review can act on
A visibility percentage is not a reviewable artefact. Medical, legal and regulatory reviewers need the AI-generated claim itself, the date, the engine, and how it diverges from approved prescribing information or company guidance — documented, not charted.
2. Awareness of the disclosure calendar
What is safe to publish changes with quiet periods, blackout windows, readouts and PDUFA dates. A dashboard has no concept of your disclosure calendar; the remediation step is where that constraint actually bites.
3. Claim-level accuracy, not share of voice
Being mentioned more often is the wrong goal when the risk is a safety profile drawn from class-level data, a mechanism of action that contradicts your label, or a statement misattributed to one of your investigators. Frequency metrics do not flag any of that.
4. Stakeholders who are not buyers
Investors before a readout, physicians before an advisory board, journalists researching trial results, acquirers forming a first impression. Marketing-funnel framing does not describe this audience set.
5. Someone to correct the record within constraints
Detection is the cheap half. The expensive half is producing correction-ready content that legal, IR and medical affairs will actually approve, and getting it in front of the systems generating the answer.
What QuestionFuel does in this category
Summarised rather than re-explained — each item links to the page that covers it properly.
Narrative monitoring built around regulatory moments
Monitoring cadence set to your calendar — weekly, biweekly or monthly as standard, daily through readouts, PDUFA dates and earnings windows — with alerts when a material narrative shift appears.
Biopharma AI visibility and narrative monitoringDocumentation an MLR process can review
Discrepancies between AI-generated answers and official communications are documented as an audit trail rather than a score, which is what makes compliance oversight of AI-sourced information possible.
AI visibility for life sciencesClinical-stage asset narratives
Narrative integrity work specific to an asset in development, where phase status, data interpretation and competitive positioning are the fields AI most often gets wrong.
Narrative integrity for clinical-stage assetsSignal integrity across sources
Tracing which sources AI is drawing on — abstracts, competitor filings, outdated press — so corrections target the material actually feeding the answer.
AI signal integrity for life sciencesDevice and diagnostics categories
The same work applied where AI recommendations reach HCP purchasing decisions rather than investors, including competitive category descriptions and evidence claims.
Who this applies to across life sciencesWorking inside disclosure constraints
Engagements operate within quiet periods and Regulation FD, reports are delivered under NDA, and correction strategies are checked against disclosure obligations before anything is implemented.
Request a confidential reviewWhat we do not offer
No dashboard, no API, no MCP server, no prompt quota and no published price list. If continuous multi-engine measurement with executive reporting is the requirement, a tracker is the correct purchase and many life sciences teams should run one alongside this work. Terminology is defined in the biopharma AI visibility glossary.
Sources
Profound — www.tryprofound.com/solutions/pr-teams, read 2026-08-01.
Peec.ai — peec.ai/, read 2026-08-01.
Otterly.ai — otterly.ai/pricing/, read 2026-08-01.
Claims about other vendors describe their own published positioning on the date shown. Capabilities move quickly here — if something is out of date, tell us and we will correct it.
Common questions
Can we use a generic AI visibility tracker in life sciences?
Yes, and for measurement you probably should. A tracker queries the same engines whether your category is footwear or oncology, so the data collection is not the problem. What none of them publishes is a regulated-industry workflow: Profound organises its solutions for AEO, content and PR & brand teams, Peec.ai describes itself as AI search analytics for marketing teams, and Otterly.ai tiers its plans for solo marketers through global brands. That is a positioning statement about who they built for, not a claim that their tracking is inaccurate.
What makes AI visibility different for biopharma?
Three things. The output has to survive medical, legal and regulatory review, so a visibility percentage is not usable on its own. The publishing side is constrained by quiet periods, blackout windows and Regulation FD, so remediation timing is a compliance question. And the risk is claim-level accuracy — safety profiles built from class-level data, mechanisms that contradict the label, KOL statements misattributed — rather than how often you are mentioned.
Is share of voice a useful metric for a drug asset?
Rarely as the primary one. Being described more often is not progress if the description is wrong, and for a clinical-stage asset an inaccurate answer during a high-attention window carries more perception risk than a low mention count. Accuracy against official communications is the metric that matters first; frequency is secondary.
Do you monitor during a quiet period?
Yes. Monitoring is observation, not disclosure, and it is arguably most valuable during a blackout because the information vacuum gets filled by abstracts, competitor filings and outdated press. Any correction work that follows is reviewed against your disclosure obligations before implementation, and reports are delivered under NDA.
Does QuestionFuel offer a dashboard, API or self-serve plan for this?
No. There is no dashboard, no API and no published price list — real gaps against every tracker on the market. Findings arrive as documentation and correction-ready content. If a live multi-engine dashboard is the requirement, buy a tracker; the two are complements more often than substitutes.
Explore this topic →How does this relate to AEO generally?
The underlying discipline is the same — making a business legible to systems that generate answers. Life sciences differs in what the consequences of a wrong answer are and in who has to approve the fix, not in the mechanics of how models read your material.
Explore this topic →Request a Confidential Life Sciences Review
A confidential diagnostic of how AI systems currently describe your company, lead asset, clinical data and pipeline — documented so your medical, legal and IR teams can act on it.
Confidential and under NDA. We work within quiet periods and blackout schedules.